Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 18, 2010, Pages 5567-5571

  Lee, Ki Ho ^a,b   Park, Chun Eung ^b   Min, Kyung Hyun ^b   Shin, Yong Je ^b   Chung, Coo Min ^b   Kim, Hui Ho ^b   Yoon, Hae Jeoung ^b   Won Kim, ^b   Ryu, Eun Ju ^b   Shin, Yu Jin ^b   Nam, Hyun Sik ^b   Cho, Jeong Woo ^b   Lee, Hee Yoon ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Life Science Division   (South Korea)

Author keywords

Antidepressant; Depression; Dopamine; Inhibitor; Norepinephrine; Reuptake; Serotonin

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 3 ARYL 3 AZOLYLPROPAN 1 AMINE; FLUOXETINE; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; EVALUATION; FEMALE; IC 50; MAXIMUM PLASMA CONCENTRATION; MICROSOME; MOTOR ACTIVITY; NONHUMAN; RAT; SINGLE DRUG DOSE; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANQUILIZING ACTIVITY;

ANALGESICS; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE; HUMANS; MICE; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PROPYLAMINES; RATS; SEROTONIN; TETRAZOLES;

EID: 77956169846     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.021     Document Type: Article

References (36)

1. M.J. Millan Pharmacol. Ther. 110 2006 135
2. S. Rosenzweig-Lipson, C.E. Beyer, Z.A. Hughes, X. Khawaja, S.J. Rajarao, J.E. Malberg, Z. Rahman, R.H. Ring, and L.E. Schechter Pharmacol. Ther. 113 2007 134
3. C.B. Nemeroff Focus 6 2008 3
4. E.M. Hull, J.W. Muschamp, and S. Sato Physiol. Behav. 83 2004 291
5. M. El-Ghundi, B.F. O'Dowd, and S.R. George Rev. Neurosci. 18 2007 37
6. S. Zisook, A.J. Rush, B.R. Haight, D.C. Clines, and C.B. Rockett Biol. Psychiatry 59 2006 203
7. G.I. Papakostas, J.J. Worthington III, D.V. Iosifescu, G. Kinrys, A.M. Burns, L.B. Fisher, C.H. Homberger, D. Mischoulon, and M. Fava Depress. Anxiety 23 2006 178
8. M.E. Breuer, J.S. Chan, R.S. Oosting, L. Groenink, S.M. Korte, U. Campbell, R. Schreiber, T. Hanania, E.M. Snoeren, M. Waldinger, and B. Olivier Eur. Neuropsychopharmacol. 18 2008 908
9. Y. Liang, A.M. Shaw, M. Boules, S. Briody, J. Robinson, A. Oliveros, E. Blazar, K. Williams, Y. Zhang, P.R. Carlier, and E. Richelson J. Pharmacol. Exp. Ther. 327 2008 573
10. Y. Liang, and E. Richelson Psychiatry 15 2008 50
11. S.R. Tella, B. Ladenheim, and J.L. Cadet J. Pharmacol. Exp. Ther. 281 1997 508
12. L.C. Daws Pharmacol. Ther. 121 2009 89
13. P. Skolnick, P. Krieter, J. Tizzano, P. Popik, P. Czobor, and A. Lippa CNS Drug Rev. 12 2006 123
14. NeuroSearch announcement Feb 23, 2009 (http://www.neurosearch.com ).
15. HPLC separation conditions for isomers of 13c: (Chiralpak-AD column (4.6 × 250 mm); hexane/isopropanol (0.1% DEA) = 90/10; flow rate = 1 mL/min; column temperature = 27 °C); isomer 1 (13d) 15.45 min, isomer 2 (13e) 16.79 min.
16. A. Gomtsyan, R. Koenig, and C.-H. Lee J. Org. Chem. 66 2001 3613
17. HPLC separation conditions for isomers of 19q and 19t: (Chiralpak-AD column (4.6 × 250 mm); hexane/isopropanol (0.1% DEA) = 90/10; flow rate = 1 mL/min; column temperature = 27 °C); isomer 1 (19r) 8.64 min, isomer 2 (19s) 9.57 min; isomer 1 (19u) 8.36 min, isomer 2 (19v) 8.97 min.
18. A. Kamal, G.B.R. Khanna, and R. Ramu Tetrahedron: Asymmetry 13 2002 2039
19. 3H]DA uptake: all tests were conducted by MDS Pharma Services-Taiwan Ltd, Taipei, Taiwan.
20. The rat and human microsomal stability assays were able to accurately determine half-lives of up to 60 min.
21. R.D. Porsolt, M. Le Pichon, and M. Jalfre Nature 266 1977 730
22. DOV216,303 was prepared in house and submitted to assay.
23. N. Aubin, P. Barneoud, C. Carter, D. Caille, N. Sontag, C. Marc, J. Lolivier, A. Gardes, C. Perron, A. Le Kim, T. Charieras, M. Pandini, P. Burnier, F. Puech, S. Jegham, P. George, B. Scatton, and O. Curet J. Pharmacol. Exp. Ther. 310 2004 1171
24. S. Boulton, and L. Handley Psychopharmacologia 31 1972 205
25. O. Nakagawasai, Y. Arai, S.E. Satoh, N. Satoh, M. Neda, M. Hozumi, R. Oka, H. Hiraga, and T. Tadano Neurotoxicology 25 2004 223
26. L. Stéru, R. Chermat, B. Thierry, and P. Simon Psychopharmacology 85 1985 367
27. N. Ripoll, D.J. David, E. Dailly, M. Hascoët, and M. Bourin Behav. Brain Res. 143 2003 193
28. L. Stéru, R. Chermat, B. Thierry, J.A. Mico, A. Lenegre, M. Steru, P. Simon, and R.D. Porsolt Prog. Neuropsychopharmacol. Biol. Psychiatry 11 1987 659
29. I. Korzeniewska-Rybicka, and A. Płaźnik Pharmacol. Biochem. Behav. 59 1988 331
30. M.O. Rojas-Corrales, J. Casas, M.R. Moreno-Brea, J. Gibert-Rahola, and J.A. Micó Eur. Neuropsychopharmacol. 13 2003 355
31. M. Aoki, M. Tsuji, H. Takeda, Y. Harada, J. Nohara, T. Matsumiya, and H. Chiba Eur. J. Pharmacol. 550 2006 78
32. M. Abe, H. Nakai, R. Tabata, K.I. Saito, and M. Egawa Jpn. J. Pharmacol. 76 1998 297
33. H. Takeuchi, S. Yatsugi, and T. Yamaguchi Jpn. J. Pharmacol. 90 2002 197
34. W.A. McKim Drugs and Behavior: Psychomotor Stimulants 2000 Prentice-Hall New Jersey p 236
35. R.J. Rodgers, J. Randall, and B. Kelway Neurosci. Lett. 58 1985 97
36. M. Brocco, A. Dekeyne, S. Veiga, S. Girardon, and M.J. Millan Pharmacol. Biochem. Behav. 71 2002 667